BMY — Bristol-Myers Squibb Company

Is BMY overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - General

Overbought As of July 5, 2026

Bristol-Myers Squibb Company (BMY) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of July 5, 2026. The Healthcare name (Drug Manufacturers - General) last closed at $58.13. The rating moved from Neutral to Overbought on July 3, 2026 and has changed 29 times in the last 90 days.

Public ratingOverbought (as of July 5, 2026)
Last close$58.13
Rating changesRating changed 29 times in the last 90 days
Last changeMoved from Neutral to Overbought on July 3, 2026
SectorHealthcare
IndustryDrug Manufacturers - General

Latest MarketMoodz coverage

Salesforce reportedly to buy Fin for $3.6B to beef up Agentforce AI2026-06-15
Takeda’s AI-Designed Zasocitinib Tops Sotyktu in Phase 32026-06-11
Space-made drugs: PIL-BOX pushes pharma into orbit2026-06-09
Sanofi, Owkin Deepen AI Tie with Agentic AI Initiative2026-06-05
Bristol Myers, Hengrui Team Up — China Emerges as R&D Hub2026-05-15

See today's live rating, score and targets

Members see the live hourly rating for BMY — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.